In a recent piece in Forbes, former president of Pfizer research and development John LaMattina discusses the limitations of the popular antidepressants classified as selective serotonin reuptake inhibitors, or SSRIs.
LaMattina mentions an antidepressant that pharmaceutical company Lundbeck is developing, called Lu AA21004. He writes that researchers are hoping the new medication won’t have some of the drawbacks of SSRIs, which include Prozac and Zoloft.
Those drawbacks, according to LaMattina, include a ...
continue reading...
Some consumer groups are complaining about legislation that recently passed in the U.S. Senate, accusing Congress of passing up an opportunity to keep unsafe medical devices off the market – such as DePuy Orthopaedics 
New research indicates that the use of oral contraceptives by younger women may be linked with inflammatory bowel disease, according to an article in U.S. News and World Report.
British surgeons have developed a stem cell procedure that they hope will prevent a condition commonly leading to hip joint replacement.
An article in The Vancouver Sun examines the controversy surrounding the use of antidepressants by pregnant women.
According to a study published in the New England Journal of Medicine, aspirin may be just as effective a long-term treatment for blood clots as commonly prescribed blood thinners such as warfarin, while carrying less risk of bleeding.
